Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
Mark E. Issa, Farnaz Sedigheh Takhsha, Chandra Sekhar Chirumamilla, et al.
Clinical Epigenetics (2017) Vol. 9, Iss. 1
Open Access | Times Cited: 74

Showing 26-50 of 74 citing articles:

Polymeric nanomedicines targeting hematological malignancies
Wenxing Gu, Ruobing Qu, Fenghua Meng, et al.
Journal of Controlled Release (2021) Vol. 337, pp. 571-588
Open Access | Times Cited: 25
SETD4 expression is correlated with leukemic burden and SMYD2 transcription in acute lymphoblastic leukemia
Luis Augusto Muniz Telles, Mariana Braccialli de Loyola, Luís Carlos Sakamoto, et al.
Research Square (Research Square) (2025)
Closed Access
Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
Marcelo Lima Ribeiro, Diana Reyes-Garau, Marc Armengol, et al.
Frontiers in Genetics (2019) Vol. 10
Open Access | Times Cited: 28
Single‐Cell RNA Sequencing in Hematological Diseases
Yue Zhu, Yao‐Hui Huang, Yun Tan, et al.
PROTEOMICS (2020) Vol. 20, Iss. 13
Closed Access | Times Cited: 27
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a
Tengteng Yu, Chenxing Du, Xiaoke Ma, et al.
Molecular Cancer Research (2020) Vol. 18, Iss. 7, pp. 1063-1073
Open Access | Times Cited: 26
Decoding DNA methylation in epigenetics of multiple myeloma
Ting Yang, Xiaobo Liu, Shaji Kumar, et al.
Blood Reviews (2021) Vol. 51, pp. 100872-100872
Closed Access | Times Cited: 22
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Holger W. Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
American Journal of Hematology (2021) Vol. 96, Iss. 6, pp. 708-718
Open Access | Times Cited: 21
Optimization Of Cancer Treatment Through Overcoming Drug Resistance
Yahya Elshimali, Yong Wu, Hussein Khaddour, et al.
Journal of Cancer Research and Oncobiology (2018) Vol. 1, Iss. 2
Open Access | Times Cited: 26
Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells
Shan Lu, Viola B. Morris, Vinod Labhasetwar
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 370, Iss. 3, pp. 902-910
Open Access | Times Cited: 24
Insight into the Basic Mechanisms and Various Modulation Strategies Involved in Cancer Drug Resistance
Devdhar Yadav, GSN Koteswara Rao, Deepika Paliwal, et al.
Current Cancer Drug Targets (2023) Vol. 23, Iss. 10, pp. 778-791
Closed Access | Times Cited: 7
Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
Mohammad Alzrigat, Helena Jernberg‐Wiklund, Jonathan D. Licht
Epigenomes (2018) Vol. 2, Iss. 3, pp. 16-16
Open Access | Times Cited: 23
Epigenetics of Skeletal Diseases
Álvaro del Real, Leyre Riancho‐Zarrabeitia, Laura López-Delgado, et al.
Current Osteoporosis Reports (2018) Vol. 16, Iss. 3, pp. 246-255
Open Access | Times Cited: 22
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
Chia‐Hung Yen, Hui‐Hua Hsiao
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3503-3503
Open Access | Times Cited: 21
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 12
TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma
Han-Yue Xue, Wei Fang
Annals of Hematology (2024) Vol. 103, Iss. 11, pp. 4351-4362
Open Access | Times Cited: 2
Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells
Daniela Lamorte, Immacolata Faraone, Ilaria Laurenzana, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3348-3348
Open Access | Times Cited: 20
Dual Inhibition of H3K9me2 and H3K27me3 Promotes Tumor Cell Senescence without Triggering the Secretion of SASP
Na Zhang, Mengjie Shang, Hongxin Li, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3911-3911
Open Access | Times Cited: 11
Cancer Chemoresistance; Recent Challenges and Future Considerations
Muhammad Adil, Shamsa Kanwal, Sarmad Rasheed, et al.
Cancer treatment and research (2023), pp. 237-253
Closed Access | Times Cited: 6
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
Li Xu, Juan Feng, Hailong Tang, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 4
Open Access | Times Cited: 15
Viral Causality of Human Cancer and Potential Roles of Human Endogenous Retroviruses in the Multi-Omics Era: An Evolutionary Epidemiology Review
Konstantina Kitsou, Maria Iliopoulou, Vana Spoulou, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 14
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
Jacob P. Laubach, Sascha A. Tuchman, Jacalyn Rosenblatt, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 2
Open Access | Times Cited: 13
Data-Driven Math Model of FLT3-ITD Acute Myeloid Leukemia Reveals Potential Therapeutic Targets
David J. Wooten, Melat T. Gebru, Hong‐Gang Wang, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 3, pp. 193-193
Open Access | Times Cited: 13
Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells
Emilie Logie, Chandra Sekhar Chirumamilla, Claudina Pérez-Novo, et al.
Cancers (2021) Vol. 13, Iss. 7, pp. 1618-1618
Open Access | Times Cited: 13
EPHA3 Contributes to Epigenetic Suppression of PTEN in Radioresistant Head and Neck Cancer
Song‐Hee Kim, Byung Chul Kang, Daseul Seong, et al.
Biomolecules (2021) Vol. 11, Iss. 4, pp. 599-599
Open Access | Times Cited: 13
Genomic and epigenomic evolution of acquired resistance to combination therapy in esophageal squamous cell carcinoma
Qingjie Min, Yan Wang, Qingnan Wu, et al.
JCI Insight (2021) Vol. 6, Iss. 17
Open Access | Times Cited: 13

Scroll to top